Work

MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors

Year: 2014
Type: article
Abstract: // Yuan-Shuo Hsueh 1 , Hui Hua Chang 2 , Nai-Jung Chiang 1,3 , Chueh-Chuan Yen 4,5 , Chien-Feng Li 1,6,7,8 and Li-Tzong Chen 1,2,3,9 1 National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan 2 Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan 3 Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan 4 Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan 5 National Yang-Ming University School of Medicine, Taipei, Taiwan 6 Department of Pathology, Chi-Mei Foundation Medical Center, Tainan, Taiwan 7 Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan 8 Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan 9 Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwann Correspondence: Li-Tzong Chen, email: // Chien-Feng Li, email: // Keywords : gastrointestinal stromal tumor, KIT, heat shock protein 90 inhibitor, MTOR inhibitor, autophagy Received : June 19, 2014 Accepted : October 21, 2014 Published : October 21, 2014 Abstract Our previous study demonstrated NVP-AUY922, a HSP90AA1 inhibitor, could enhance mutant KIT degradation in gastrointestinal stromal tumor (GIST) cells through both proteasome- and autophagy-mediated pathways. Herein, we showed rapamycin, a MTOR inhibitor and autophagy inducer, could reduce total and phospho-KIT expression levels and enhance apoptosis in imatinib-resistant GIST cells. The involvement of autophagy in rapamycin-induced KIT downregulation was further confirmed by co-localization of KIT and autophagosome, and partial recovery of KIT expression level by either siRNA-mediated BECN1 and ATG5 silencing or autophagy inhibitors after rapamycin. Rapamycin and NVP-AUY922 synergistically inhibited GIST cells growth in vitro . The combination of low-dose NVP-AUY922 with rapamycin had comparable effects on reducing KIT expression, increasing MAP1LC3B puncta and tumor necrosis, and inhibiting tumor growth as high-dose NVP-AUY922 did in GIST430 xenograft model. Our results suggest the addition of a MTOR inhibitor may reduce NVP-AUY922 dose requirement and potentially improve its therapeutic index in mutant KIT-expressing GISTs.
Source: Oncotarget
Language: English
Field: Medicine
Open Access status: diamond
OpenAlex ID: W1732266052
FWCI: 2.478
Cites: 51
Cited by: 34
Related to: 10